Australia’s active vaccine safety system

Nirsevimab

Vaccine safety data

AusVaxSafety has been conducting active safety surveillance of Beyfortus (nirsevimab) – a new long-acting injectable monoclonal antibody product used for the prevention of severe respiratory syncytial virus (RSV) disease in infants – at participating sites in New South Wales and Queensland throughout the 2024 winter season.

In Australia, nirsevimab is currently only available to infants and young children through state-managed programs in New South Wales, Queensland and Western Australia.

Safety data are gathered via surveys sent to recipients in the days following nirsevimab administration.

The Western Australia RSV immunisation program also includes active safety surveillance, with reports published through Government of Western Australia Department of Health channels.

As the end of the 2024 winter season approaches and 2024 state-based programs finish, the use of nirsevimab is expected to slow. Unfortunately, AusVaxSafety do not have enough data to enable meaningful analysis for 2024.

Plans for surveillance of nirsevimab in 2025 are currently under consideration and will be informed by future nirsevimab programs. AusVaxSafety will update this page as 2025 nirsevimab surveillance plans materialise.

Vaccine safety data

News & events

All news & events

AusVaxSafety receives funding
from the Australian Government

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433  |  Fax (612) 9845 1418  |  ABN 53 188 579 090

We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Copyright © 2022 AusVaxSafety. All rights reserved

vaccine

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433  |  Fax (612) 9845 1418  |  ABN 53 188 579 090

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.